Read + Share
Amedeo Smart
Independent Medical Education
Mesa R, Harrison C, Oh ST, Gerds AT, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 2022;36:2261-2268.PMID: 35869266
Email
LinkedIn
Facebook
Twitter
Privacy Policy